ym 872 has been researched along with c.i. 42510 in 2 studies
| Studies (ym 872) | Trials (ym 872) | Recent Studies (post-2010) (ym 872) | Studies (c.i. 42510) | Trials (c.i. 42510) | Recent Studies (post-2010) (c.i. 42510) |
|---|---|---|---|---|---|
| 41 | 0 | 5 | 4,960 | 190 | 1,366 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bartlett, CA; Fitzgerald, M; Gopalasingam, G; Majimbi, M; Rodger, J; Toomey, LM | 1 |
| Bartlett, CA; Fitzgerald, M; Gavriel, N; Gopalasingam, G; Majimbi, M; McGonigle, T; Rodger, J; Toomey, LM | 1 |
2 other study(ies) available for ym 872 and c.i. 42510
| Article | Year |
|---|---|
Comparison of ion channel inhibitor combinations for limiting secondary degeneration following partial optic nerve transection.
Topics: Animals; Calcium Channel Blockers; Calcium-Binding Proteins; Cell Adhesion Molecules, Neuronal; Disease Models, Animal; Drug Delivery Systems; Drug Therapy, Combination; Ectodysplasins; Female; Imidazoles; Ion Channels; Macrophages; Microfilament Proteins; Microglia; Nerve Degeneration; Nystagmus, Optokinetic; Oligodendrocyte Transcription Factor 2; Optic Nerve Injuries; Piperazines; Quinoxalines; Rats; Receptor, Platelet-Derived Growth Factor alpha; Rosaniline Dyes; Tubulin | 2019 |
Comparing modes of delivery of a combination of ion channel inhibitors for limiting secondary degeneration following partial optic nerve transection.
Topics: Animals; Calcium Channel Blockers; Calcium Channels; Drug Therapy, Combination; Female; Imidazoles; Myelin Sheath; Nerve Degeneration; Optic Nerve; Optic Nerve Injuries; Piperazines; Quinoxalines; Rats; Receptors, AMPA; Receptors, Purinergic P2X7; Rosaniline Dyes | 2019 |